Medpace insider sale: Director McCarthy disposes 1,662 shares at $465.04

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) director Cornelius P. McCarthy III reported a sale of 1,662 shares of Medpace common stock on 08/19/2025 under Form 4. The sale is coded S and executed at a weighted average price of $465.04 per share (individual trade prices ranged from $465.022 to $465.355). After the reported transactions, the reporting person beneficially owned 10,197 shares, held directly. The Form 4 was signed by an attorney-in-fact, Stephen P. Ewald, on 08/21/2025. The filer is identified as a director of the company and the filing indicates compliance with Section 16 reporting obligations.

Positive

• Transparent disclosure of the sale with weighted average price and range provided
• Compliance with Section 16 reporting including attorney-in-fact signature

Negative

• Reduction in director's direct ownership from undisclosed prior levels to 10,197 shares after sale
• Sale of 1,662 shares could be interpreted as insider liquidity, depending on prior holdings and timing

Insights

Financial Analyst

TL;DR Director sold 1,662 shares on 08/19/2025 at a weighted average of $465.04, leaving 10,197 shares.

This Form 4 documents a routine insider sale by a company director rather than an option exercise or derivative transaction. The transaction code "S" confirms outright sale of common stock. The weighted average price and the disclosed range indicate the shares were sold in multiple executions during the day. From a holdings perspective, the director retains a meaningful but reduced direct stake of 10,197 shares after the sale. The filing appears complete for the reported transaction and follows Section 16 reporting format.

Corporate Governance Expert

TL;DR The filing shows a disclosed, direct sale by a director with proper Section 16 reporting and attorney-in-fact signature.

The report identifies the reporting person as a director and includes an attorney-in-fact signature, which is an accepted practice when authorized representatives file on behalf of insiders. The explanation clarifies that the price shown is a weighted average from multiple trades and offers to provide full pricing details upon request, supporting transparency. No derivatives, option exercises, or related-party transactions are reported in this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCarthy Cornelius P. III

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		S		1,662	D	$465.04(1)	10,197	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $465.022 to $465.355. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Cornelius P. McCarthy III	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MEDP director Cornelius P. McCarthy III report on Form 4?

The director reported an outright sale of 1,662 shares of Medpace common stock on 08/19/2025 at a weighted average price of $465.04 per share.

How many Medpace shares does the reporting person own after the sale?

After the reported transactions the reporting person beneficially owned 10,197 shares, held directly.

What does transaction code 'S' mean on this Form 4?

Transaction code S denotes a sale of securities, indicating the shares were sold rather than acquired or transferred under another code.

What pricing information is disclosed for the sale?

The Form 4 reports a weighted average price of $465.04 and states individual sale prices ranged from $465.022 to $465.355.

Who signed the Form 4 and when?

The Form 4 was signed by Stephen P. Ewald, Attorney-in-Fact, on 08/21/2025.